After establishing an efficient gene replacement method for SH3TC2, we proceeded with a randomized, mock vector-controlled, blinded treatment trial by intrathecal injection in groups of Sh3tc2−/− littermate mice at 3 weeks of age, at early stages of neuropathy. The gene discussed is SH3TC2; the disease is neuropathy.